We are inviting start-ups in Germany, Austria, and Switzerland, developing digital solutions that are driving change for people at risk of or living with cardiovascular diseases (CVD).

We are committed to driving change in Diabetes by tackling the related health challenges through innovative medicines and approaches, including new digital solutions.

As over time, high blood sugar can damage blood vessels and nerves controlling the heart, people living with Type 2 Diabetes are facing the risk of or are having a range of CVDs including heart failure, stroke, and coronary artery disease. These complications can be life-threatening for around 50% of people living with Type 2 Diabetes. Therefore, it is even more important to take good care of your heart when you have Diabetes.

The Digital CVD Fast Track Innovation Program is looking for start-ups or scale-ups of all sizes, preferably from seed stage funding onwards, with digital solutions in the Diabetes and/or CVD space that can have a positive impact on the patient treatment path.

 

Today, many people living with Type 2 Diabetes are not aware of these complications and are not being identified early enough in order to prevent CVD complications. We are looking for digital solutions that raise awareness and/or increase activation of people living with or at risk of CVDs. 

It is challenging for people living with Type 2 Diabetes to be stratified according to the risk level of facing potential CVDs associated with the chronic disease. We are looking for digital identification and/or diagnosis solutions for people living with or at risk of CVDs.

CVD prevention is enhanced by lifestyle changes and adherence to healthy behaviours and existing treatment therapies. We are looking for solutions, e.g. Digital Therapeutics (DTx), that enable this behaviour change and increase adherence. 

The Digital CVD Fast Track Innovation Program will support one digital solution with non-equity pilot funding with up to 100.000€*, depending upon the scope of work and required resources to deliver a seamless patient experience.

The selected start-up will be working closely with Novo Nordisk, a multinational pharma company leader in Diabetes management. You will work closely with medical, marketing & digital teams in Germany during the pilot implementation.

Opportunity to get exposure to the Novo Nordisk network, including our newly launched Novo Nordisk Digital Innovation Hubs located across the globe in the top 6 best health tech ecosystems ​ 

 

*By submitting your proposal and by participating the Digital CVD Fast Track Innovation Program, you do not have any legal claim to receive a specific funding sum from Novo Nordisk Pharma GmbH.

The Fast Track Innovation journey

Step 1: The Digital CVD Fast Track Innovation Program

The challenge is open for start-ups and scale-ups to submit their proposals for the Digital CVD Fast Track Innovation program in Germany, Switzerland and Austria directly from this webpage. The application deadline is 9th of January 2023.​

Step 1: The Digital CVD Fast Track Innovation Program

The challenge is open for start-ups and scale-ups to submit their proposals for the Digital CVD Fast Track Innovation program in Germany, Switzerland and Austria directly from this webpage. The application deadline is 9th of January 2023.​

Step 2: Selection of top start-ups and scale-ups​

A panel of experts will review the proposals and select the most promising digital solutions providers to be brought forward for the pitch day.​

Step 2: Selection of top start-ups and scale-ups​

A panel of experts will review the proposals and select the most promising digital solutions providers to be brought forward for the pitch day.​

Step 3: Pitch Day​

All selected digital solution providers will be invited to pitch their solutions. The pitch day will take place in February 2023. ​

Step 3: Pitch Day​

All selected digital solution providers will be invited to pitch their solutions. The pitch day will take place in February 2023. ​

Step 4: Pilot and implementation

The selected pilot will be supported by Novo Nordisk Pharma GmbH with funding to pilot their solution.

Step 4: Pilot and implementation

The selected pilot will be supported by Novo Nordisk Pharma GmbH with funding to pilot their solution.